Allison Sharrow, PhD: Academic-to-Industry Transition
Allison Sharrow, PhD, has more than 20 years of experience researching complex biomedical diseases, with a particular focus on overcoming chemoresistance in ovarian cancer. In this time, she has seen academic research change due to bad incentives. As she transitions her career out of academia, Sharrow is using the analytical and communication skills she learned along the way to educate investors and entrepreneurs to grow the commercial life science ecosystem in her hometown of Pittsburgh, PA.
Allison—QUICK LINKS:
“Diverse emerging managers can have access to differentiated deal flow that tends to be less crowded and enables them to make meaningful investments with smaller check sizes. They often look to add value beyond capital through networks and industry expertise. — What a wonderful insight supporting diversity in venture capital! The rest of the trend analysis is also interesting.” #Bias
“I am inspired to see a female-driven investment firm investing in a wonderful female founder in Pittsburgh. Thank you Chloe Capital for seeking to fill a gap in the industry and for recognizing the impact that Anne Germain and NOCTEM Health will have on insomnia.” #Bias
“Early detection in ovarian cancer has been a long-standing goal to help drive improvements in survival from this deadly cancer. I deeply hope that AOA Dx achieves where others have failed. I enthusiastically await the results of your trial!” #Transfer
“Congratulations to Velo.ai for being selected for the 2024 RealLIST and to Astrata, Inc for being listed as a runner-up!” #Transfer #Maturation
